PGR (Progesterone receptor)

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	palbociclib + inavolisib Sensitive: A1 - Approval palbociclib + inavolisib Sensitive : A1	palbociclib + inavolisib Sensitive: A1 - Approval palbociclib + inavolisib Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	letrozole Sensitive: A1 - Approval letrozole Sensitive : A1	letrozole Sensitive: A1 - Approval letrozole Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	anastrozole Sensitive: A1 - Approval anastrozole Sensitive : A1	anastrozole Sensitive: A1 - Approval anastrozole Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
AKT1 mutation + HR positive	HER2 Negative Breast Cancer	AKT1 mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PTEN mutation + HR positive	HER2 Negative Breast Cancer	PTEN mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
HR negative + BRCA1 mutation	HER2 Negative Breast Cancer	HR negative + BRCA1 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HR positive + HER-2 negative	Male Breast Cancer	HR positive + HER-2 negative	Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	toremifene Sensitive: A2 - Guideline toremifene Sensitive : A2	toremifene Sensitive: A2 - Guideline toremifene Sensitive : A2
HR negative + BRCA2 mutation	HER2 Negative Breast Cancer	HR negative + BRCA2 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	HER2 inhibitor Sensitive: A2 - Guideline HER2 inhibitor Sensitive : A2	HER2 inhibitor Sensitive: A2 - Guideline HER2 inhibitor Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	HER2 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline HER2 inhibitor + Aromatase inhibitor Sensitive : A2	HER2 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline HER2 inhibitor + Aromatase inhibitor Sensitive : A2
HR positive + HER-2 negative	Male Breast Cancer	HR positive + HER-2 negative	Male Breast Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2

PGR (Progesterone receptor)

Associations(374)

Associations
(374)